摘要
目的:探讨雌激素对卵巢癌细胞HO-8910的IL-6合成和分泌的调节.方法:采用体外实验方法用不同浓度的雌二醇(E2)和其受体拮抗剂作用卵巢癌细胞HO-8910,用ELISA法检测培养细胞上清液中IL-6的含量,细胞免疫化学法检测IL-6在细胞中的定位和量的变化.结果:1×10-6,1×10-8和1×10-10mol/L的E2培养细胞3 d后,细胞上清液中IL-6的量分别增加93.42%,82.89%和22.37%,较对照有显著性差异(P<0.05),细胞免疫化学染色见HO-8910细胞中IL-6表达上调.加用雌激素受体拮抗剂ICI 182780组未检测到IL-6合成和分泌的增加.结论:E2通过与其受体结合,促进卵巢癌细胞HO-8910合成和分泌IL-6,这可能是雌激素致卵巢癌及激素替代治疗增加卵巢癌术后患者复发风险的机制之一.
AIM： To discuss estradiol in the regulation of interleukin-6 （IL-6） excretion and synthesis of ovarian cancer cell HO-89]0. METHODS： Different concentrations of estradiol （E2 ） and its receptor antagonist were used to affect HO-89]0 in vitro. IL-6 content of cell culture supernatant was detected by ELISA. IL-6 and the localization and dose change in cells were examined by immunohisto-chemical method. RESULTS： 1 ×10^-6, 1 × 10^-8 and 1 × 10^-10 mol/L E2 were co-cultivated with cells for 3 d and the concentration of IL-6 in cell culture supernatant increased by 93.42%, 82.89% and 22.37% respectively. They were significantly higher than those in controls （ P 〈0. 05 ）. Immunohistochemical staining showed that IL-6 was expressed in nuclear membrane. The group using E2 receptor antagonist ICI 182780 had no difference with the controls. CONCLUSION： E2 binding with its receptor accelerates the ovarian cancer cell HO-8910 to synthesize and secrete IL-6, which may increase the risk of hormone replacement therapy in ovarian cancer patients after operation.
出处
《第四军医大学学报》
北大核心
2005年第22期2028-2030,共3页
Journal of the Fourth Military Medical University
作者简介
逯蕾（1967-）,女（汉族）,甘肃省天水市人.主治医师,硕士生（导师辛晓燕）.Tel.（029）82245800 Email.lulei1128@126.com
